Four biotechs and a Matthew Roden-led SPAC price IPOs, raising a combined $528M

Four more biotechs and a SPAC led by Bristol Myers Squibb vet Matthew Roden have priced IPOs, closing out another busy week on Wall Street.

Together, Praxis Precision Medicines, Tarsus Pharmaceuticals, Aligos Therapeutics, Kiromic BioPharma and Turmeric Acquisition — MPM’s blank check company — have raised $528 million on their public debuts.